Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06874751 · ClinicalTrials.gov registry record
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World
A clinical trial, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- 45,456
- Enrollment target
NCT06874751: Completed study, sponsored by Novo Nordisk A/S.
NCT06874751 is a clinical trial that has completed, run by Novo Nordisk A/S. The registered enrollment target is 45,456 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06874751 has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- 45,456 participants
- Enrollment target
Study Summary
This is a retrospective database study which includes administrative medical and pharmacy claims linked with clinical and laboratory measurements for patients in the US, to evaluate the effectiveness of once-weekly semaglutide 2.4 mg in reducing the risk of CV and other obesity-related clinical outcomes.
Primary Outcome
Measured as months Occurrence of any of the following individual component events: 1. Myocardial Infarction (MI) 2. Stroke 3. Hospitalization for Heart Failure (HF) 4. Coronary revascularization 5. All-cause mortality The event date will be the earliest occurrence of one of the individual components.
Interventions
- OTHER No treatment given
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45,456 participants |
| Start Date | 2024-12-06 |
| Est. Completion | 2025-03-28 |
What the finished NCT06874751 record still lists
NCT06874751 is an observational study that tracks outcomes without assigning an intervention. Its 45,456 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which No treatment given is the first listed.
NCT06874751 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06874751 about?
NCT06874751 is a clinical study titled "Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World". This is a retrospective database study which includes administrative medical and pharmacy claims linked with clinical and laboratory measurements for patients in the US, to evaluate the effectiveness of once-weekly semaglutide 2.4 mg in reducing the risk of CV and other obesity-related clinical outc...
What is the current status of trial NCT06874751?
This trial is currently completed. The enrollment target is 45,456 participants. The study started on 2024-12-06. Estimated completion is 2025-03-28.
What interventions are being tested in trial NCT06874751?
The interventions under investigation include: No treatment given (OTHER).
Who is sponsoring clinical trial NCT06874751?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06824350 · 45,450 participants · NA
Clean Trial - Chlorination to Reduce Enteric and Antibiotic Resistant Infections in Neonates
- NCT05607732 · 45,257 participants · NA
Primary Care Detection of Cognitive Impairment Leveraging Health & Consumer Technologies in Underserved Communities: The MyCog Trial
- NCT06597968 · 45,991 participants
Evaluating the Real World Performance of an AI Based Lung Nodule Detection Tool
- NCT03977402 · 47,500 participants
Total Cancer Care Protocol: A Lifetime Partnership With Patients Who Have or May be at Risk of Having Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI